These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 22616830)

  • 1. Drotrecogin alfa (activated) in adults with septic shock.
    Ranieri VM; Thompson BT; Barie PS; Dhainaut JF; Douglas IS; Finfer S; Gårdlund B; Marshall JC; Rhodes A; Artigas A; Payen D; Tenhunen J; Al-Khalidi HR; Thompson V; Janes J; Macias WL; Vangerow B; Williams MD;
    N Engl J Med; 2012 May; 366(22):2055-64. PubMed ID: 22616830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dream deferred: the rise and fall of recombinant activated protein C.
    Holder AL; Huang DT
    Crit Care; 2013 Mar; 17(2):309. PubMed ID: 23509922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial.
    Póvoa P; Salluh JI; Martinez ML; Guillamat-Prats R; Gallup D; Al-Khalidi HR; Thompson BT; Ranieri VM; Artigas A
    Crit Care; 2015 Apr; 19(1):193. PubMed ID: 25928214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
    Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
    N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
    Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
    Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock.
    Spapen H; Nguyen DN; Troubleyn J; Huyghens L; Schiettecatte J
    Crit Care; 2010; 14(2):R54. PubMed ID: 20374626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
    Nadel S; Goldstein B; Williams MD; Dalton H; Peters M; Macias WL; Abd-Allah SA; Levy H; Angle R; Wang D; Sundin DP; Giroir B;
    Lancet; 2007 Mar; 369(9564):836-843. PubMed ID: 17350452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).
    Shorr AF; Nelson DR; Wyncoll DL; Reinhart K; Brunkhorst F; Vail GM; Janes J
    Crit Care; 2008; 12(2):R45. PubMed ID: 18394162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; Booth FV
    Surgery; 2007 Apr; 141(4):548-61. PubMed ID: 17431957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
    Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
    Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.
    Bertolini G; Rossi C; Anghileri A; Livigni S; Addis A; Poole D
    Intensive Care Med; 2007 Mar; 33(3):426-34. PubMed ID: 17325836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).
    Levi M; Levy M; Williams MD; Douglas I; Artigas A; Antonelli M; Wyncoll D; Janes J; Booth FV; Wang D; Sundin DP; Macias WL;
    Am J Respir Crit Care Med; 2007 Sep; 176(5):483-90. PubMed ID: 17556722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated).
    Levy H; Laterre PF; Bates B; Qualy RL
    Crit Care; 2005 Oct; 9(5):R502-7. PubMed ID: 16277711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial.
    Heming N; Renault A; Kuperminc E; Brun-Buisson C; Megarbane B; Quenot JP; Siami S; Cariou A; Forceville X; Schwebel C; Leone M; Timsit JF; Misset B; Benali MA; Colin G; Souweine B; Asehnoune K; Mercier E; Chimot L; Charpentier C; François B; Boulain T; Petitpas F; Constantin JM; Dhonneur G; Baudin F; Combes A; Bohé J; Loriferne JF; Cook F; Slama M; Leroy O; Capellier G; Dargent A; Hissem T; Bounab R; Maxime V; Moine P; Bellissant E; Annane D; ;
    Lancet Respir Med; 2024 May; 12(5):366-374. PubMed ID: 38310918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial.
    Annane D; Timsit JF; Megarbane B; Martin C; Misset B; Mourvillier B; Siami S; Chagnon JL; Constantin JM; Petitpas F; Souweine B; Amathieu R; Forceville X; Charpentier C; Tesnière A; Chastre J; Bohe J; Colin G; Cariou A; Renault A; Brun-Buisson C; Bellissant E;
    Am J Respir Crit Care Med; 2013 May; 187(10):1091-7. PubMed ID: 23525934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).
    Short MA; Schlichting D; Qualy RL
    Curr Med Res Opin; 2006 Dec; 22(12):2525-40. PubMed ID: 17265595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.
    Laterre PF; Garber G; Levy H; Wunderink R; Kinasewitz GT; Sollet JP; Maki DG; Bates B; Yan SC; Dhainaut JF;
    Crit Care Med; 2005 May; 33(5):952-61. PubMed ID: 15891319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
    N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.